Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00660088 · ClinicalTrials.gov registry record
Safety of Three Formulations of Ketasyn Administered for 14 Days in Healthy Elderly
A clinical trial of Alzheimers Disease, sponsored by Cerecin.
- Completed
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT00660088: Completed study of Alzheimers Disease, sponsored by Cerecin.
NCT00660088 is a study of Alzheimers Disease that has completed, run by Cerecin. The registered enrollment target is 60 participants, below the 3,926-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00660088, a study of Alzheimers Disease, has completed, sponsored by Cerecin.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
AC-1202 (Ketasyn) is a nutritional beverage currently being studied in neurodegenerative conditions including Alzheimer's disease. The current study is a randomized, open-label trial to compare the safety, tolerability, and PK profiles of 3 formulations of Ketasyn administered on a daily basis for 14 days, with and without a 7-day titration period, in normal, healthy elderly volunteers.
Conditions Studied
Interventions
- OTHER Ketasyn
Study Locations (1)
Florida
- Meridien Research Center - St. Petersburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2008-04 |
| Est. Completion | 2008-08 |
What the finished NCT00660088 record still lists
NCT00660088 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 3,926-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 1 intervention - of which Ketasyn is the first listed.
NCT00660088 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00660088 about?
NCT00660088 is a clinical study titled "Safety of Three Formulations of Ketasyn Administered for 14 Days in Healthy Elderly". AC-1202 (Ketasyn) is a nutritional beverage currently being studied in neurodegenerative conditions including Alzheimer's disease. The current study is a randomized, open-label trial to compare the safety, tolerability, and PK profiles of 3 formulations of Ketasyn administered on a daily basis for 1...
What is the current status of trial NCT00660088?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2008-04. Estimated completion is 2008-08.
What conditions does trial NCT00660088 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT00660088?
The interventions under investigation include: Ketasyn (OTHER).
Who is sponsoring clinical trial NCT00660088?
This trial is sponsored by Cerecin, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00660088 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00660088's enrollment target sits among peer trials
60 86th of 147 higher than 59 of 147 other Alzheimers Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
University of Central Florida Music Study
RECRUITING · NA
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia